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The cause of lung cancer is generally attributed to tobacco smoking. However lung cancer in never smokers
accounts for 10 to 25% of all lung cancer cases. Arsenic, asbestos and radon are three prominent non-tobacco
carcinogens strongly associated with lung cancer. Exposure to these agents can lead to genetic and epigenetic
alterations in tumor genomes, impacting genes and pathways involved in lung cancer development. Moreover,
these agents not only exhibit unique mechanisms in causing genomic alterations, but also exert deleterious effects
through common mechanisms, such as oxidative stress, commonly associated with carcinogenesis. This article
provides a comprehensive review of arsenic, asbestos, and radon induced molecular mechanisms responsible for
the generation of genetic and epigenetic alterations in lung cancer. A better understanding of the mode of
action of these carcinogens will facilitate the prevention and management of lung cancer related to such
environmental hazards.Background
Lung cancer is commonly associated with tobacco
smoke exposure. However, lung cancer in never smokers
accounts for 10 to 25% of all cases, ranking as the 7th
most common cause of cancer-related death [1,2]. As
lung cancer in never smokers is thought to develop
through molecular pathways different from those
induced by tobacco, the study of non-tobacco related
carcinogens is fundamental to better understand the
biology of lung tumors arising in never smokers [1-5].
Arsenic, asbestos and radon are well known human
carcinogens, based on evidence derived from human and
animal studies [6,7]. These three agents have been
strongly linked to lung cancer development, both in
smoker and never smokers [5,8-19]. Due to its wide dis-
tribution on a global scale (Figure 1), chronic exposure
to these agents poses a significant public health problem.
Millions of people, including those who never smoke,
are at risk of developing lung cancer induced by arsenic,
asbestos and radon.
The carcinogenic effects due to exposure to these ele-
ments are well documented [5,8,9]. Table 1 summarizes
different sources that provide scientific information* Correspondence: rhubaux@bccrc.ca
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reproduction in any medium, provided the orlinking exposure to these agents with lung cancer and
other diseases. These lung carcinogens can induce a
wide range of molecular alterations, including genetic
(from specific point mutations to genome-wide aberra-
tions) and epigenetic (including alterations in DNA
methylation, and microRNA expression) [25]. Consider-
ing the relevance of this issue to public health, this art-
icle highlights the specific molecular events associated
with exposure to arsenic, asbestos and radon as environ-
mental carcinogens driving lung cancer.
Environmental evidence for lung carcinogenesis induced
by arsenic, asbestos and radon
Arsenic
Arsenic, a naturally occurring metalloid in earth’s crust, is
a well-established human carcinogen [7]. Exposure occurs
mainly through drinking water, but also via air and food
[22,26]. Arsenic contamination has been considered the
largest mass poisoning in mankind’s history, since ~160
million people live in regions with naturally elevated levels
of arsenic in drinking water [27]. Health effects, including
lung cancer, have been documented with chronic exposure
at levels below the currently accepted threshold of 10μg/L
[3,27-29] – and at such dosage several hundred million
individuals would be affected.
Although skin cancer is the most common form of
malignancy associated with arsenic exposure, lung, asl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Worldwide occurrence of asbestos, arsenic and radon. Regions known to be affected by contamination with asbestos are colored
coded in yellow (production >100,000 tons in 2010), blue (consumption >10,000 tons in 1970) and purple (consumption >10,000 tons in 2010).
The five largest producers of asbestos (yellow) in 2010 were Russia (1 million tons), China (0.35 million tons), Brazil (0.27 million tons), Kazakhstan
(0.23 million tons) and Canada (0.1 million tons). *Zimbabwe produced 0.15 million tons in 2003 but its production was banned in 2004;
however, a controversial production revival plan is expected. Countries with current high consumption of asbestos (purple) are distinguished
from countries that had previously high consumption prior to the last decades (blue). Grey indicates consumption of less than 10,000 tons per
year. Asbestos production and consumption trends (from 1900 through 2003 and for 2010) are provided by the US Geological Survey (USGS)
[20,21]. Areas with known occurrence of arsenic in ground water at >50μg/L (red circles) are estimated using information retrieved from the
International Groundwater Resources Assessment Centre (USGS) [22]. Areas reported (non-exhaustive) to have high radon levels are depicted by
green circles. Radon occurrence was based on 238U detected in soil and country radon levels (UNSCEAR, WHO, USGS) [23,24]. Circle placement
was determined by approximation; for detailed information, see references as information availability differed from country to country.
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of arsenic carcinogenesis [2,30]. Lung cancer is in fact
the main cause of death following chronic arsenic inges-
tion, and this metalloid is considered as a risk factor for
lung cancer in never smokers [2,5,26,31]. Augmented
levels of arsenic in drinking water have been associated
with an increase in the incidence of lung cancer. In the
United States alone, an estimated 5,297 arsenic-related
lung cancer cases per year are associated with arsenic
exposure [32]. Moreover, arsenic exposure contributes
synergistically with other risks factors such as tobacco
smoke and history of lung disease [29,33]. The most fre-
quent histological subtypes observed in arsenic-induced
lung tumors are squamous cell carcinomas (SqCC) and
small cell carcinomas (SCC), which are unusual in
tumors arising in never smokers [29,34-37]. Lung SqCC
associated with arsenic exposure exhibit unique patterns
of genomic alterations, raising the possibility of arsenic-
specific oncogenic pathways [37].
Asbestos
Asbestos are mineral fibers found naturally in rocks and
widely used by industry. Exposure to asbestos fibers,
such as chrysotile, amosite, anthophyllite and mixed
fibers containing crocidolite, has resulted in a highincidence of lung cancer [6]. Like arsenic, asbestos can
act independently or synergistically with tobacco smoke
to induce lung cancer [6,38].
Asbestos fibers, with the exception of crocidolite,
cause at least twice as many lung cancer deaths than
asbestos-related mesothelioma, and these two malignan-
cies combined are responsible for nearly 10,000 deaths
per year in the United States [39,40]. The relative risk
for developing lung cancer among individuals exposed
to asbestos was more than 3 times higher than for non-
exposed individuals after controlling for smoking, among
other variables [41]. Asbestos-induced effects in the
lungs are dose-dependent and are related to the type of
fiber inhaled and its composition, such as iron-rich
fibers, which are more redox reactive [38,42-45]. Other
fibers, such as libby amphibole transition fibers and erio-
nite, although not classified in the asbestos mineral
group, have also been implicated in asbestos-associated
diseases, suggesting that other thin mineral fibers may
have carcinogenic properties similar to those found in
asbestos [42]. Even though the current use and manage-
ment of asbestos is under strict control in most countries,
the high latency between exposure and asbestos-related
disease development poses a significant public health
threat [46]
Table 1 Sources of information on environmental carcinogens associated with lung cancer
Name Website Description
The IARC Monographs, International Agency for
Research on Cancer (IARC)
http://monographs.iarc.fr/ Compilation of reports about environmental factors that can
increase the risk of human cancer: chemicals, complex
mixtures, occupational exposures, physical agents, biological
agents, and lifestyle factors
Carcinogens, American Cancer Society (ACS) http://www.cancer.org/Cancer/
CancerCauses/OtherCarcinogens/
index
Information about environmental carcinogens that can be
found at home, work, pollution, medical tests and treatments






Compilation of slides on environment and its association
with cancer





Information on the 10 chemicals or groups of chemicals of
major public health concern





Congressionally mandated, science-based, public health
reports that identify agents, substances, mixtures, or exposures
in the environment that may potentially put people in the
United States at increased risk for cancer




Information on human health impacts associated with
environmental exposures
Work-Related Lung Disease (WoRLD) Surveillance




Contents on occupationally-related respiratory disease
surveillance data.
U.S. Geological Survey (USGS) http://www.usgs.gov/ Organization that provides impartial information on the health
of U.S. environment and the natural hazards
CARcinogen EXposure Canadian Surveillance
Project (CAREX)
http://www.carexcanada.ca Multi-institution research project that combines academic
expertise and government resources to generate an evidence-
based carcinogen surveillance program for Canada
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Radon is a radioactive gas formed naturally by the break-
down of uranium from soils and rocks. Exposure to this
gas is estimated to be associated with more than 20,000
lung cancer deaths per year in the United States [47-49].
Radon accounts for more than 50% of the annual effective
dose of natural radioactivity exposure [50], affecting not
only miners but also the general population as a ubiquitous
contaminant of water and indoor environments [50,51].
The relationship between radon and lung cancer has
mainly been established from epidemiologic studies of
underground miners [52]. Specifically, non-smoking ur-
anium miners in the southwestern United States experi-
enced an increased incidence of lung cancer [53,54].
Further analysis established that up to 70% of lung can-
cer deaths among uranium miners can be attributed to
radon exposure, and the risk of lung cancer among non-
smoking miners was up to 3 times higher than in other
occupations [48,50,55]. It has been estimated that up to
30% of lung cancer deaths among non-occupationally
exposed never-smokers might be linked to indoor radon
[48]. The maximum accepted level in most countries is
currently 200 Bq/m3; however, studies have established
an elevated lung cancer risk at radon levels as low as
100 Bq/m3 [56,57].Carcinogenic mechanisms induced by exposure to
arsenic, asbestos, and radon
Arsenic
Carcinogenesis of arsenic is related to its biotransform-
ation process. When arsenic enters the body, it induces
a series of reduction, oxidation, and methylation reac-
tions (Figure 2) [63]. Pentavalent arsenical species (AsV
or arsenate) are reduced to trivalent species (AsIII or
arsenite) in a glutathione (GSH)-dependent reaction
[64], followed by oxidative methylation resulting in
monomethylarsonous acid (MMAIII), methylarsonate
(MMAV) or dimethylarsenate (DMAV) [65-67]. Some of
the methylated metabolites generated in the detoxifica-
tion process may in fact be more potent carcinogens
than inorganic non-methylated species [58-60].
Arsenate interferes with phosphorylation reactions and
competes with phosphate transport, while arsenite can
react with the sulfhydryl groups of proteins, resulting in
inhibition of many biochemical pathways [68]. It is also
well established that free radicals are generated during
the process of arsenic metabolism [69-73]. By interfering
with enzymes that control redox status and glutathione
production, arsenic compounds, especially trivalent spe-
cies, inhibit the protection of cells against oxidative
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Figure 2 Arsenic biotransformation drives carcinogenesis. Arsenic biotransformation occurs through a series of reduction, oxidation, and
methylation reactions. Pentavalent arsenic (AsV) is reduced to arsenite (AsIII), using glutathione (GSH) and thioredoxin (TRX) as electron donors. In
the excretion process of this compound, AsIII is methylated using S-Adenosyl methionine (SAM) as a source of methyl groups; however, this result
in generation of arsenic species with higher carcinogenic potential [58-62]. Carcinogenic effects are mostly generated due to this biotransformation
process, having effects at genetic and epigenetic levels. Genetic alterations are largely due to generation of reactive oxygen species (ROS) and reactive
nitrogen species (RNS), partially derived from arsenic-induced mitochondrial dysfunction. Epigenetic effects, such as changes in DNA methylation
patterns have been linked to deprivation of SAM. Changes in miRNA expression and histone modifications have also been reported.
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with mtDNA deletions and depletions which contribute
to carcinogenicity in humans [75,76]. Under these condi-
tions, mitochondria is considered to be the primary site
of superoxide anion (•O2-) formation [69]. After forma-
tion of •O2- in arsenic-induced oxidative stress, a cas-
cade of secondary reactive oxygen species (ROS), suchas hydrogen peroxide (H2O2) and hydroxyl radical
(•OH) is generated [70]. The hydroxyl radical is one of
the most impactful ROS and reacts with DNA to produce
8-Hydroxy-2’-deoxyguanosine, a major ROS-induced
DNA base-modified product [71,77]. Furthermore, gluta-
thione depletion induced by arsenic may increase its
toxicity via ROS-related damage [71,78].
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Inhaled asbestos fibers longer than 5μm are not effi-
ciently eliminated by phagocytosis. This can induce a
cascade of molecular events that lead to fibrosis, inflam-
mation and carcinogenesis [79,80]. On the other hand,
fully phagocytized fibers can interfere with mitosis, lead-
ing to chromosomal missegregation [81] (Figure 3). The
induction of reactive oxygen and nitrogen species upon
incomplete phagocytosis of fibers plays an important
role in DNA damage [84]. Asbestos induces the release
of ROS, including •O2- and H2O2 [79]. Such reactions
can be catalyzed on the asbestos fiber surface, andDNA  
damage 


















Figure 3 Mechanisms of asbestos-induced carcinogenesis. Inhaled asb
translocations, or undergo phagocytosis [44,82,83]. Fibers not efficiently elim
species (ROS and RNS, respectively) which can lead to generation of DNA s
effects. Epigenetic changes, such as alterations in miRNA expression and D
asbestos fibers. Alternately, fully phagocytized fibers can physically interfere
anchoring to mitotic structures.asbestos fibers with high iron content, such as crocido-
lite and amosite, are capable of generating higher levels
of ROS [85]. Similar to arsenic, asbestos also affects
mitochondrial DNA and functional electron transport
resulting in mitochondrial-derived ROS, which has been
shown to induce base oxidation, single-strand breaks,
micronuclei, and apoptosis in lung alveolar epithelial
cells. [86,87]. Therefore, asbestos carcinogenesis is sus-
pected to occur through creation of an environment of
chronic inflammation, and especially through the induc-
tion of oxidative stress, a well-known inducer of DNA
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mechanisms in asbestos-induced neoplasia in lungs and
other target organs [89]. Direct asbestos mutagenicity
has also been proposed as a mode of action for asbestos,
although this theory requires further study [89,90].
Radon
Although chemically inert, radon decays into active pro-
genies that are electrically charged and can be inhaled
when attached to natural aerosols, eventually reaching
lung epithelial cells. Once in the lung tissue, deposited
radon progeny decays to generate alpha-particles, which
damage DNA both directly and through generation of free
radicals (Figure 4) [51]. Decay of alpha-particles results inRado













Figure 4 Radon induces reactive oxygen species through emission of
214Po) that can be inhaled when attached to natural particles in aerosol [50
can lead to generation of reactive oxygen species (ROS), eventually resultin
affecting neighboring non-irradiated cells [51]. Additionally, changes in DNthe ejection of electrons from water, generating several
reactive species leading to cellular damage by hydroxyl
radical attack [92,93]. Cellular damage can also occur in
nearby, non-irradiated bystander cells through the release
of chemical byproducts by irradiated cells [94]. This ‘by-
stander’ effect can result in non-linear dose–response
damage and underestimation of radon exposure risks [95].
In fact, it has been proposed that lung tissue cellular injury
from alpha particles is predominantly due to chromo-
somal damage in neighboring non-irradiated cells [96].
Moreover, after exposure to alpha-particle radiation, ob-
servable levels of cytokines are detected in the superna-
tants of exposed cells, implying a possible effect of
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genomes due to arsenic, asbestos and radon exposure
The mechanisms discussed above lead to specific genetic
alterations including mutations and chromosomal rear-
rangements, as well as epigenetic changes, meaning
mechanisms of gene expression disruption that do not
modify the DNA sequence itself, such as DNA methyla-
tion, histone modifications and microRNA (miRNA)
regulation [98]. Although there have been several reports
of specific genetic alterations in lung cancer in never
smokers, only a few studies have directly linked such
alterations with specific environmental carcinogens.Table 2 Genetic alterations occurring in environmentally
induced lung cancer
CNA* at Locus Carcinogen References
1q21.1 Arsenic [37]
2p21-p16 Asbestos [120] S, [121,122]
Ch.5 Asbestos [112] CLMolecular and genetic alterations
Arsenic
Moderate levels of arsenic activate the EGFR pathway in
human lungs and other target organs of arsenic-carcino-
genesis, such as the liver [68,99]. Moreover, arsenic-
induced ROS activate the Wnt/β-catenin signaling path-
way (which has been shown to promote lung cancer), and
stimulate angiogenesis through AKT and ERK1/2 [100-
102]. In murine lung tissue, arsenic interferes with expres-
sion and protein levels of components of DNA repair ma-
chinery, such as APE1, LIG1, OGG1, PARP1 [103].
DMAV has been able to induce lung-specific DNA
strand breaks by arsenic-mediated production of ROS in
mice [104]. Arsenic has been shown to increase the fre-
quency of micronuclei in cultivated cells from human
small airways [105]. Compared to tumors of non-
exposed individuals, DNA losses at chromosomal locus
1q21.1 and gains at 19q13.31 and 19q13.33 have been
observed lung squamous cell carcinoma (SqCC) in ar-
senic exposed never smokers [37]. In human small air-
way epithelial cells arsenic increases expression of
cancer related genes and protein levels, such as C-MYC,
C-HA-RAS, and C-FOS and decreases β4 integrin pro-
tein expression compared with non-exposed cells [105].5q35 Asbestos [120] S, [122]
Ch.8 Asbestos [112] CL
9p21.3 (CDKN2A) Radon, Asbestos [123] R, [111]
12p12.1 (KRAS**) Asbestos [124]
16p13.3 Asbestos [122]
17p13.1 (TP53**) Asbestos [110] S
Ch.19 Asbestos [112] CL
19p13.3-13.1 Asbestos [120] S, [122]
19q13.31 Arsenic [37]
19q13.33 (SPIB, NR1H2, POLD1) Arsenic [37]
22q12.3-q13.1 Asbestos [122]
Xq28 Asbestos [120]
* CNA = copy number alteration.
** Sequence mutation.
References include both smokers and non smokers except if indicated
(S: smokers only, CL: Cell Lines, R: rat).Asbestos
In lung epithelial cells, asbestos-induced glutathione de-
pletion results in phosphorylation and activation of
EGFR, overexpression of different AP-1 proto-onco-
genes, and AP-1 transactivation [106]. In human epithe-
lial bronchial cell lines (Beas-2B), asbestos exposure
induces a range of gene expression alterations, affecting
MAP4K3, CEBPZ, QPCT, FANCG, IGFBPL1, CCL19,
MELK, FANCM, and CDKL1 [107]. Asbestos inhalation
also causes up-regulation of mRNA levels of matrix
metalloproteinase family members in rat lungs, suggest-
ing induction of extracellular matrix remodeling [108].
Mutations in the KRAS and TP53 genes have been
detected in animal models human tumors linked to as-
bestos exposure, although these alterations have notbeen conclusively associated with asbestos exposure
Nelson, 1999 #387, [109,110].
A higher frequency of deletions affecting the P16/
CDKN2A locus has been identified in asbestos-exposed
non-small cell lung cancer cases compared to unexposed
cases, which represent a main gene inactivation mechan-
ism, although no differences were reported linked to
smoking status [111]. Changes at chromosomes 5, 8 and
19 have been detected in HBECs transformed by chryso-
tile asbestos [112]. Additionally, asbestos interferes with
chromosomal segregation by interacting directly with
microtubules and chromosomes [113-116].
Radon
Inhaled particles of radon generate alpha-emissions that
cause DNA damage primarily through double-strand
breaks and large chromosomal aberrations, mainly dele-
tions and, to a lesser extent, point mutations [117,118].
Specific mutational events have been described in
radon-induced lung cancer. Vahakangas et al. detected
both P53 mutations and deletions in lung tumors from
uranium miners. Although the contribution of tobacco
smoke cannot be completely ruled out, the most fre-
quent base substitutions associated with tobacco smok-
ing (G:C to T:A transversions), were not identified in
that study [119].
Table 2 summarizes the most known genetic altera-
tions observed in lung cancer associated with exposure
to these three carcinogens. Specific genetic alterations
Table 3 Epigenetic alterations occurring in
environmentally induced lung cancer
Type of alteration Carcinogen Gene References
Hypermethylation Radon, CDKN2A [132,135,136]
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cinogen, for example, DNA losses at chromosomal locus
1q21.1 and gains at 19q13.31 and 19q13.33 are asso-
ciated with arsenic exposure in never smokers [37].Asbestos















Arsenic miR-200 [131] CL
miR Asbestos miR-148b, miR-374a, [134] SEpigenetic alterations
Specific alterations at the epigenetic level, such as modi-
fications in DNA methylation and microRNA (miRNA)
expression patterns, have been associated with arsenic,
asbestos and radon exposure. Aberrant methylation of
CpG islands in the promoter region of tumor suppressor
genes (TSGs) are linked to gene silencing, while deregu-
lation of miRNAs − small, noncoding RNAs species that
regulate gene expression − is implicated in diverse
human pathologies, including lung cancer (reviewed in










Studies concern both smokers and non smokers except if indicated (S:
smokers only, CL: Cell Lines).Arsenic
Arsenic induces promoter hypermethylation and subse-
quent transcriptional silencing of tumor suppressors
genes, such as P53, CDKN2A and RASSF1A in animal
models [129,130]. Chronic arsenic exposure depleted
miR-200 levels in human bronchial epithelial cells
(HBECs) through increased promoter methylation, and
interestingly, re-established expression of miR-200b alone
was capable of entirely reversing and preventing arsenic-
induced EMTand malignant transformation [131].Asbestos
Epigenetic inactivation of tumor-suppressor genes, such
as RASSF1A and CDKN2A (p16) has been observed in
lung cancer patients exposed to asbestos [132]. Interest-
ingly, p16 has been found to be inactivated in NSCLC
tumors from nonsmokers only through promoter hyper-
methylation [133]. A recent study has identified an
asbestos-associated miRNA signature in lung cancer,
where miR-148b, miR-374a, miR-24-1*, let-7d, Let-7e,
miR-199b-5p, miR-331-3p, and miR-96, were found to
be over-expressed, while miR-939, miR-671-5p, miR-605,
miR-1224-5p and miR-202 were under-expressed [134].Radon
Long-term radon exposure has been associated with
increased CDKN2A and MGMT promoter methylation
among Chinese miners [135]. The locus containing the
CDKN2A gene is in fact frequently affected by DNA losses
in radon-induced lung tumors in rats [123]. Interestingly,
exposure to plutonium, which similar to radon exerts its
effects through alpha particles, can induce CDKN2A gene
inactivation by promoter methylation [136].
Table 3 summarizes epigenetic changes observed in lung
tumors associated with exposure to these three agents.Management strategies for radon, arsenic and asbestos
exposure
Geological carcinogen mapping plays an essential role in
risk management. Examples of geological maps for radon
and arsenic can be found on websites from U.S. Environ-
mental Protection Agency as well as from the U.S.
Geological Survey (Table 1). Similar maps for Canada are
available from the CAREX (CARcinogen EXposure)
Canadian surveillance project website (www.carexcanada.
ca). Mapping these carcinogens will help to determine oc-
currence of co-exposure its health consequences, and the
urgency for specific management strategies.
Methods for arsenic removal from water include oxi-
dation, precipitation, coagulation, adsorption, nanofiltra-
tion, reverse osmosis, and even bioremediation [143]. A
cost-effective technique is based on Arsenic Removal
Using Bottom Ash (ARUBA) whereby particles of coal
bottom ash (a waste material from coal fired power
plants), coated with iron hydroxide react with and
immobilize arsenic by adsorption and/or co-precipitation.
In Bangladesh, ARUBA has been shown to reduce arsenic
concentrations in contaminated groundwater to below the
Bangladesh safety threshold [144]. Non-viable fungal bio-
masses of Aspergillus niger coated with iron oxide have
also been shown to remove approximately 95% of As(V)
and 75% of As(III) from aqueous solutions [145].
The issue of asbestos is more amendable to control
since the release of asbestos into the environment origi-
nates from human activity. Most developed countries
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egies, such as the Italian directives for the remediation
of asbestos-cement roofs to be treated prior to disposal
on landfill [146]. Some processes are able to eliminate
the hazard of these wastes in order to recycle mineral
components in new building materials [147,148].
Asbestos-cement wastes are milled in a cyclic process
leading to mineralogical and morphological transforma-
tions of asbestos while keeping interesting physical prop-
erties for building use. On the other hand, two million
metric tons of asbestos were consumed in developing
countries in 2007, illustrating the need for regulating the
use of this carcinogen in developing nations [149].
Strategies against radon rely on radiation detectors
and implementation of radon-resistant features; for ex-
ample, houses in potentially high exposure zones should
be equipped with pipes to vent radon gas generated in
the ground, and sealed with plastic sheeting and caulk-
ing. Ideally, active mitigation techniques involving phys-
ical alterations such as sub-slab depressurization should
be instigated, as these methods are more effective [150].Conclusions
In the next decades, an increasing proportion of lung
cancer cases will arise in former or never smokers.
While the reduction of environmental carcinogen expos-
ure is certainly a very important cancer prevention issue,
understanding the mechanisms of carcinogenesis will fa-
cilitate targeted treatment design.
Although tobacco smoke is the major cause of lung
cancer, environmental carcinogens, such as arsenic, as-
bestos and radon play an increasingly important role in
this disease, either independently or through additive or
multiplicative effects [151,152]. While the number of
individuals exposed to these carcinogens is significant,
the difficulty to associate tumor cases directly with ex-
posure to these agents (mainly due to the long latency
period between exposure and disease onset) may be
highly underestimated.
The growing interest in non-tobacco induced causes
of lung cancer is reflected in the increasing number of
reports describing molecular alterations correlated with
exposure to these carcinogens. In this article, we have
collected evidence of the involvement of specific mo-
lecular mechanisms that can lead to genetic and epigen-
etic aberrations in lung tumor genomes as a result of
exposure to these agents. While sharing a few carcino-
genic mechanisms, each agent may induce specific sets of
alterations which might affect tumor biology and define
tumor behavior, presenting therefore a unique opportunity
for developing diagnostic and treatment options. Future
research, including the integration of different genetic and
epigenetic dimensions, will further the characterization ofthese etiologically distinct tumors and identify actionable
candidates for therapeutic targets.
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